Development and clinical overview of trastuzumab (herceptin)
1Comprehensive Cancer Research Group/Intercenter Cancer Research Group, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA.
Objectives:
To provide a review of the two pivotal clinical trials evaluating trastuzumab in metastatic breast cancer, either in combination with chemotherapy or as a single agent.
Data Sources:
Research reports.
Conclusions:
Trastuzumab is indicated as a single agent or in combination with chemotherapy for patients with metastatic breast cancer who overexpress the HER2 protein. The toxicity profile of trastuzumab is favorable; cardiac dysfunction has been the primary dose-limiting toxicity, especially when combined with anthracyclines.
Implications For Nursing Practice:
Nurses will deliver trastuzumab in the clinical setting and must be familiar with its efficacy and toxicity profile.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Clinical Trials: Overview
Preclinical Development: Overview
Tumor Immunotherapy


